Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03926481
Other study ID # D19091
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date July 10, 2019
Est. completion date March 20, 2020

Study information

Verified date August 2022
Source Dartmouth-Hitchcock Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this study is to conduct a program of pilot research aimed at evaluating the effect of an intensive lifestyle intervention on cognitive functioning in older adults with obesity and or obesity and sarcopenia.


Description:

Detailed Description: The national epidemic of obesity is also affecting older adults, and is associated with an increased risk of disability, nursing home placement and early mortality. The overarching goal of this study is to conduct a program of pilot research aimed at evaluating the effect of a intensive lifestyle intervention on cognitive functioning in order adults with obesity and or obesity and sarcopenia. While some degree of cognitive decline is common during the normal aging process, epidemiological evidence suggests that obesity can promote its acceleration. It is unclear the effect that intensive lifestyle changes could have on cognitive functioning in older adults with obesity. Study Timeline: May 2019 to May 2023 Goal: Conduct a study to evaluate the effects that intensive lifestyle program has on cognitive functioning in older adults with obesity and or obesity and sarcopenia. Participation Duration: Participants will meet weekly for 17 weeks. Cognitive assessments will take place at baseline and 17 weeks.


Recruitment information / eligibility

Status Terminated
Enrollment 6
Est. completion date March 20, 2020
Est. primary completion date March 20, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria: - English Speaking - Age =65 years - Body Composition Body Fat >25% for Men - Body Composition Body Fat >30% for Women - Participating in the Dartmouth Hitchcock Weight and Wellness Center (WWC) Healthy Lifestyle Program (HLP) - Willing and able to give informed consent Exclusion Criteria: - Unable to perform measures - Individuals unwilling/unable to provide consent - Severe mental or life-threatening illness - History of bariatric surgery

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Evaluate Healthy Lifestyle Program on cognitive outcomes
The healthy lifestyle program will be delivered once a week for 17 weeks as part as regular clinical care. It will include an group classes taught by health coaches and dieticians. These classes will focus on diet, exercise, and behavior modification. We plan 2 cohorts of 15 subjects (n=30). In-person research assistant-led assessments will occur at baseline and 17 weeks.

Locations

Country Name City State
United States Dartmouth-Hitchcock Medical Center Lebanon New Hampshire

Sponsors (1)

Lead Sponsor Collaborator
Dartmouth-Hitchcock Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in grip strength Assessed by a Jamar dynamometer. Sensor-based Thera-bands will measure data on strength change. A higher score represents a better outcome. Baseline and 17 weeks
Primary Change in 5 times Sit-to-Stand (STS) STS measures lower limb strength (minimal change 2.3 s). A higher score represents a better outcome. Baseline and 17 weeks
Primary Change in Six-Minute Walk Test (6MWT) A surrogate for cardiovascular fitness that measures distance (normal 400-700m) related to function. A clinically important difference is 50-55m Baseline and 17 weeks
Primary Change in weight in kg Change in weight in kg Baseline and 17 weeks
Primary Change in body mass index (BMI) in kg/m^2 Change in body mass index (BMI) in kg/m^2 Baseline and 17 weeks
Primary Change in subject processing speed Single Digit Modalities Test: Measure of cognition/processing speed. Score range 0 to 110. A higher score represents a better outcome. Baseline and 17 weeks
Primary Change in language function Boston Naming Test (BNT) is used to evaluate language function. Score range:0-42; higher score indicates better performance. Baseline and 17 weeks
Primary Change in subject cognition Verbal fluency test is used to evaluate language function. Performance will be identified via the total number of appropriate words responded on each of the task. Higher score indicates better performance. Baseline and 17 weeks
Primary Change in subject executive function Stroop test is used to assess executive function. Higher score indicates better performance. Raw score range: 0-300. Baseline and 17 weeks
Primary Change in speed processing Trail making Test-A&B is used to assess information processing speed. Shorter time indicates better performance. Baseline and 17 weeks
Primary Change in subject memory California Verbal Learning Test II (CVLT-II) Trials 1-5 Total raw score (range: 0-80; higher values represent a better outcome) Baseline and 17 weeks
Primary Change in Brief Visuospatial Memory Test-Revised (BVMT-R) BVMT-R is used to evaluate spatial memory ability. Scores range from 0 to 60, with higher values indicating better performance. Baseline and 17 weeks
Primary Change from baseline Anxiety Symptoms at 17 weeks will be assessed using the Generalized Anxiety Disorder-7 (GAD7). The GAD7 scores range from 5-21, with 5-9 indicating mild, 10-14 moderate, and greater than 15 severe anxiety. Baseline and 17 weeks
Primary Change from baseline Mood Symptoms at 17 weeks Will be assessed using the Patient Healthy Questionnaire (PHQ9). The PHQ9 scores range from 0-27, with lower numbers indicating minimal to no depression and higher numbers indicating severe depression. Baseline and 17 weeks
Primary Change from baseline Subjective Health Status (PROMIS) at 17 weeks Patient Reported Outcomes Measurement Information Systems (PROMIS) Global Short Form. PROMIS is a 10-item instrument capturing physical, mental and social aspects of quality of life having undergone quantitative appraisal and is non-proprietary. Higher score indicated more positive perceptions of overall health. Baseline and 17 weeks
Primary Change in Behavior Rating Inventory of Executive Function (BRIEF-A) Behavior Rating Inventory of Executive Function (BREIF-A) is used to evaluate executive functioning.This questionnaire consist of 75 items on which the patient's symptoms are rated on a 3-point Likert scale. The questionnaire provides a Global Executive Composite score (range 75-225) and two index scores: the Behavioral Regulation Index (range 30-90) and the Metacognitive Index (range 40-120) in addition to nine subscales: Inhibit (range 8-24), Shift (range 6-18), Emotional control (range 10-30), Self-monitor (range 6-18), Initiate (range 8-24), Working memory (range 8-24), Plan/organize (range 10-30), Task monitor (range 6-18) and Organization of materials (range 8-24). Higher scores indicate more executive difficulties. Baseline and 17 weeks
Primary Change in Prospective and Retrospective Memory Questionnaire (PRMQ) PRMQ is a questionnaire about daily memory difficulties. Higher scores represent worse outcomes. Total score ranges from 0-64. Baseline and 17 weeks
Secondary Baseline estimated level of intellectual ability Test of Premorbid Functioning which results in a total raw score ranging from 0-70, and is normatively scored based on respondents' age resulting in standard scores (mean = 100). Higher values indicate a higher premorbid level of intellect. Baseline
Secondary Handedness as measured by Edinburgh Handedness Inventory at Baseline A self report questionnaire assessing the dominance of one's right or left hand in everyday activities. Baseline
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2